Health Care • Biotechnology: Pharmaceutical Preparations
$8.99 ▼ -0.31
(-3.33%)
MKT CAP: $931.8M • VOL: 1.05M
52W L $7 52W H $15
ROARABLE / RQD
D- • 39/100
PIOTROSKI
2 / 9
ORIC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$143.0M | -$142.9M | -$110.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$129.5M | -$127.8M | -$100.7M |
| EBITDA (Normalized) | -$142.4M | -$141.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$111.0M | -$112.7M | -$85.7M |
| Capital Expenditures (CapEx) | $712.0K | $1.2M | — |
| Free Cash Flow (FCF) | -$111.7M | -$113.8M | -$85.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -33.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $45.7M | $59.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $384.4M | $243.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ORIC.